Sheffield W P, Blajchman M A
Canadian Red Cross Blood Services, McMaster University Medical Centre, Hamilton, Ontario.
FEBS Lett. 1995 May 29;365(2-3):189-92. doi: 10.1016/0014-5793(95)00468-o.
Heparin cofactor II (HCII) is a 66 kDa plasma glycoprotein that belongs to the serpin superfamily of protease inhibitors. Its natural target is thrombin. HCII inhibits thrombin in both a progressive reaction, and in an accelerated reaction catalyzed by a glycosaminoglycan, dermatan sulphate (DS). Both modes of inhibition result in the formation of a stable, denaturation-resistant complex. Using a cDNA clone encoding rabbit HCII recently isolated and characterized in our laboratory, we have employed deletion mutagenesis to identify amino-terminal regions of the molecular which are essential to the progressive reaction. PCR was employed to produce four deletion constructs: delta 58, delta 81, delta 106, and delta 169, all in an in vitro transcription vector plasmid background. Transcription of the full-length construct, and of the four deletion constructs, followed by in vitro translation in rabbit reticulocyte lysate, was used to produce the corresponding HCII-related polypeptides. The delta 106 and delta 169 mutants failed to react with thrombin, even in the presence of DS. In contrast, the delta 58 and delta 82 mutants retained the ability to form complexes with thrombin, although the rate of complex formation was decreased for the latter mutant compared to the full-length recombinant HCII; no acceleration of complex formation in the presence of 20 micrograms/ml DS was noted for either truncated recombinant HCII. Alignment of the rabbit HCII primary structure with secondary structural elements found in alpha 1 antitrypsin and other serpins showed that the non-functional delta 106 mutant lacks helix A, while the functional delta 82 mutant contains this element. Our results suggest that helix A is an essential part of a functional serpin, and define the limits of the amino-terminal region of HCII which is not essential for thrombin inhibition.
肝素辅因子II(HCII)是一种66 kDa的血浆糖蛋白,属于丝氨酸蛋白酶抑制剂超家族。其天然靶点是凝血酶。HCII在渐进反应以及由糖胺聚糖硫酸皮肤素(DS)催化的加速反应中均能抑制凝血酶。两种抑制模式都会导致形成稳定的、抗变性的复合物。利用我们实验室最近分离并鉴定的编码兔HCII的cDNA克隆,我们采用缺失诱变来确定分子中对渐进反应至关重要的氨基末端区域。使用PCR产生了四个缺失构建体:delta 58、delta 81、delta 106和delta 169,均处于体外转录载体质粒背景中。全长构建体以及四个缺失构建体的转录,随后在兔网织红细胞裂解物中进行体外翻译,用于产生相应的与HCII相关的多肽。delta 106和delta 169突变体即使在存在DS的情况下也无法与凝血酶反应。相比之下,delta 58和delta 82突变体保留了与凝血酶形成复合物的能力,尽管与全长重组HCII相比,后者突变体形成复合物的速率有所降低;对于任何一种截短的重组HCII,在存在20微克/毫升DS的情况下均未观察到复合物形成加速。将兔HCII一级结构与α1抗胰蛋白酶和其他丝氨酸蛋白酶抑制剂中的二级结构元件进行比对,结果表明无功能的delta 106突变体缺乏螺旋A,而有功能的delta 82突变体含有该元件。我们的结果表明螺旋A是功能性丝氨酸蛋白酶抑制剂的重要组成部分,并确定了HCII氨基末端区域对凝血酶抑制并非必需的界限。